市場調査レポート
商品コード
1161487

末梢神経障害治療の世界市場 2023-2027

Global Peripheral Neuropathy Treatment Market 2023-2027

出版日: | 発行: TechNavio | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
末梢神経障害治療の世界市場 2023-2027
出版日: 2022年11月15日
発行: TechNavio
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、末梢神経障害治療の市場規模は、2023年から2027年にかけて3億7256万米ドル、予測期間中のCAGRは3.81%で成長すると予測しています。当レポートでは、末梢神経障害治療市場の全体分析、市場規模・予測、動向、成長促進要因・課題、約25のベンダーを網羅したベンダー分析を行っています。

現在の世界の市場動向と促進要因、市場全体の環境に関する最新の分析を提供しています。

市場は、末梢神経障害の有病率の増加、末梢神経障害に対する最近の医薬品承認、末梢神経障害に対する認知度の上昇によって牽引されています。

本調査では、今後数年間における末梢神経障害治療市場の成長を促進する主要な理由の一つとして、強力な医薬品パイプラインを挙げています。また、新しい製剤による技術的進歩やジェネリック医薬品の普及が、市場の大きな需要につながると考えています。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2022
  • 市場の見通し:2022-2027年の予測

第4章 市場規模実績

  • 世界の末梢神経障害治療市場2017~2021年
  • タイプセグメント分析2017-2021
  • 治療セグメント分析2017-2021
  • 地域セグメント分析2017-2021
  • 国セグメント分析2017-2021

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 タイプ別の市場セグメンテーション

  • 市場内訳
  • タイプ別比較
  • 糖尿病性末梢神経障害 - 市場規模と予測 2022-2027
  • 化学療法による末梢神経障害 - 市場規模と予測 2022-2027
  • その他 - 市場規模と予測 2022-2027
  • タイプ別の市場機会

第7章 治療法別市場セグメンテーション

  • 市場内訳
  • 治療法別比較
  • 薬物療法 - 市場規模と予測 2022-2027
  • 非薬物療法 - 市場規模と予測 2022-2027
  • 治療法別の市場機会

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米 - 市場規模と予測 2022-2027
  • 欧州 - 市場規模と予測 2022-2027
  • アジア - 市場規模と予測 2022-2027
  • その他の地域(ROW) - 市場規模と予測 2022-2027
  • 米国 - 市場規模と予測 2022-2027
  • ドイツ - 市場規模と予測 2022-2027
  • 中国 - 市場規模と予測 2022-2027
  • 英国 - 市場規模と予測 2022-2027
  • 日本 - 市場規模と予測 2022-2027
  • 地域情勢別の市場機会

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Apotex Inc.
  • Assertio Therapeutics Inc.
  • AstraZeneca Plc
  • Cadila Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Co.
  • Endo International Plc
  • Hikma Pharmaceuticals Plc
  • Johnson and Johnson
  • Lupin Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Viatris Inc.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Therapy
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits18: Historic Market Size - Data Table on Global peripheral neuropathy treatment market 2017 - 2021 ($ million)
  • Exhibits19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • Exhibits20: Historic Market Size - Treatment Segment 2017 - 2021 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2022 and 2027
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • Exhibits29: Chart on Market condition - Five forces 2022 and 2027
  • Exhibits30: Chart on Type - Market share 2022-2027 (%)
  • Exhibits31: Data Table on Type - Market share 2022-2027 (%)
  • Exhibits32: Chart on Comparison by Type
  • Exhibits33: Data Table on Comparison by Type
  • Exhibits34: Chart on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
  • Exhibits35: Data Table on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
  • Exhibits36: Chart on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)
  • Exhibits37: Data Table on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)
  • Exhibits38: Chart on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
  • Exhibits39: Data Table on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
  • Exhibits40: Chart on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)
  • Exhibits41: Data Table on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)
  • Exhibits42: Chart on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibits43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibits44: Chart on Others - Year-over-year growth 2022-2027 (%)
  • Exhibits45: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • Exhibits46: Market opportunity by Type ($ million)
  • Exhibits47: Chart on Therapy - Market share 2022-2027 (%)
  • Exhibits48: Data Table on Therapy - Market share 2022-2027 (%)
  • Exhibits49: Chart on Comparison by Therapy
  • Exhibits50: Data Table on Comparison by Therapy
  • Exhibits51: Chart on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
  • Exhibits52: Data Table on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
  • Exhibits53: Chart on Pharmacological therapies - Year-over-year growth 2022-2027 (%)
  • Exhibits54: Data Table on Pharmacological therapies - Year-over-year growth 2022-2027 (%)
  • Exhibits55: Chart on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
  • Exhibits56: Data Table on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
  • Exhibits57: Chart on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)
  • Exhibits58: Data Table on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)
  • Exhibits59: Market opportunity by Therapy ($ million)
  • Exhibits60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits61: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits63: Chart on Geographic comparison
  • Exhibits64: Data Table on Geographic comparison
  • Exhibits65: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits67: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits68: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits71: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits75: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits81: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits82: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits83: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibits84: Data Table on US - Year-over-year growth 2022-2027 (%)
  • Exhibits85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits87: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits89: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits90: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits91: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibits92: Data Table on China - Year-over-year growth 2022-2027 (%)
  • Exhibits93: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits95: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits96: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibits98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibits99: Chart on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibits100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibits101: Market opportunity By Geographical Landscape ($ million)
  • Exhibits102: Impact of drivers and challenges in 2022 and 2027
  • Exhibits103: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits104: Overview on factors of disruption
  • Exhibits105: Impact of key risks on business
  • Exhibits106: Vendors covered
  • Exhibits107: Matrix on vendor position and classification
  • Exhibits108: Apotex Inc. - Overview
  • Exhibits109: Apotex Inc. - Product / Service
  • Exhibits110: Apotex Inc. - Key offerings
  • Exhibits111: Assertio Therapeutics Inc. - Overview
  • Exhibits112: Assertio Therapeutics Inc. - Product / Service
  • Exhibits113: Assertio Therapeutics Inc. - Key offerings
  • Exhibits114: AstraZeneca Plc - Overview
  • Exhibits115: AstraZeneca Plc - Product / Service
  • Exhibits116: AstraZeneca Plc - Key news
  • Exhibits117: AstraZeneca Plc - Key offerings
  • Exhibits118: Cadila Pharmaceuticals Ltd. - Overview
  • Exhibits119: Cadila Pharmaceuticals Ltd. - Product / Service
  • Exhibits120: Cadila Pharmaceuticals Ltd. - Key offerings
  • Exhibits121: Cipla Ltd. - Overview
  • Exhibits122: Cipla Ltd. - Business segments
  • Exhibits123: Cipla Ltd. - Key news
  • Exhibits124: Cipla Ltd. - Key offerings
  • Exhibits125: Cipla Ltd. - Segment focus
  • Exhibits126: Daiichi Sankyo Co. Ltd. - Overview
  • Exhibits127: Daiichi Sankyo Co. Ltd. - Business segments
  • Exhibits128: Daiichi Sankyo Co. Ltd. - Key news
  • Exhibits129: Daiichi Sankyo Co. Ltd. - Key offerings
  • Exhibits130: Daiichi Sankyo Co. Ltd. - Segment focus
  • Exhibits131: Dr Reddys Laboratories Ltd. - Overview
  • Exhibits132: Dr Reddys Laboratories Ltd. - Business segments
  • Exhibits133: Dr Reddys Laboratories Ltd. - Key offerings
  • Exhibits134: Dr Reddys Laboratories Ltd. - Segment focus
  • Exhibits135: Eli Lilly and Co. - Overview
  • Exhibits136: Eli Lilly and Co. - Product / Service
  • Exhibits137: Eli Lilly and Co. - Key offerings
  • Exhibits138: Endo International Plc - Overview
  • Exhibits139: Endo International Plc - Business segments
  • Exhibits140: Endo International Plc - Key news
  • Exhibits141: Endo International Plc - Key offerings
  • Exhibits142: Endo International Plc - Segment focus
  • Exhibits143: Hikma Pharmaceuticals Plc - Overview
  • Exhibits144: Hikma Pharmaceuticals Plc - Business segments
  • Exhibits145: Hikma Pharmaceuticals Plc - Key offerings
  • Exhibits146: Hikma Pharmaceuticals Plc - Segment focus
  • Exhibits147: Johnson and Johnson - Overview
  • Exhibits148: Johnson and Johnson - Business segments
  • Exhibits149: Johnson and Johnson - Key news
  • Exhibits150: Johnson and Johnson - Key offerings
  • Exhibits151: Johnson and Johnson - Segment focus
  • Exhibits152: Lupin Ltd. - Overview
  • Exhibits153: Lupin Ltd. - Product / Service
  • Exhibits154: Lupin Ltd. - Key news
  • Exhibits155: Lupin Ltd. - Key offerings
  • Exhibits156: Novartis AG - Overview
  • Exhibits157: Novartis AG - Business segments
  • Exhibits158: Novartis AG - Key offerings
  • Exhibits159: Novartis AG - Segment focus
  • Exhibits160: Pfizer Inc. - Overview
  • Exhibits161: Pfizer Inc. - Product / Service
  • Exhibits162: Pfizer Inc. - Key news
  • Exhibits163: Pfizer Inc. - Key offerings
  • Exhibits164: Viatris Inc. - Overview
  • Exhibits165: Viatris Inc. - Business segments
  • Exhibits166: Viatris Inc. - Key offerings
  • Exhibits167: Viatris Inc. - Segment focus
  • Exhibits168: Inclusions checklist
  • Exhibits169: Exclusions checklist
  • Exhibits170: Currency conversion rates for US$
  • Exhibits171: Research methodology
  • Exhibits172: Validation techniques employed for market sizing
  • Exhibits173: Information sources
  • Exhibits174: List of abbreviations
目次
Product Code: IRTNTR45413

Technavio has been monitoring the peripheral neuropathy treatment market and is poised to grow by $372.56 mn from 2023-2027, accelerating at a CAGR of 3.81% during the forecast period. Our report on the peripheral neuropathy treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of peripheral neuropathy, recent drug approvals for peripheral neuropathy, and raising awareness of peripheral neuropathy.

Technavio's peripheral neuropathy treatment market is segmented as below:

By Type

  • Diabetic peripheral neuropathy
  • Chemotherapy-induced peripheral neuropathy
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the strong drug pipeline as one of the prime reasons driving the peripheral neuropathy treatment market growth during the next few years. Also, technological advances with new formulations of drugs and rising penetration of generic drugs will lead to sizable demand in the market.

Technavio presents a detailed picture of the market through the study, synthesis, and summation of data from multiple sources through an analysis of key parameters. Our report on the peripheral neuropathy treatment market covers the following areas:

  • Peripheral neuropathy treatment market sizing
  • Peripheral neuropathy treatment market forecast
  • Peripheral neuropathy treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading peripheral neuropathy treatment market vendors that include Apotex Inc., Assertio Therapeutics Inc., AstraZeneca Plc, Cadila Pharmaceuticals Ltd., Cipla Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Grunenthal GmbH, Hikma Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Novartis AG, Pfizer Inc., Shionogi and Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and Viatris Inc. Also, the peripheral neuropathy treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market through the study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global peripheral neuropathy treatment market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on Global peripheral neuropathy treatment market 2017 - 2021 ($ million)
  • 4.2 Type Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • 4.3 Treatment Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Treatment Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

  • 6.1 Market segments
  • Exhibit 30: Chart on Type - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
  • 6.2 Comparison by Type
  • Exhibit 32: Chart on Comparison by Type
  • Exhibit 33: Data Table on Comparison by Type
  • 6.3 Diabetic peripheral neuropathy - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)
  • 6.4 Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)
  • 6.5 Others - Market size and forecast 2022-2027
  • Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
  • Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • 6.6 Market opportunity by Type
  • Exhibit 46: Market opportunity by Type ($ million)

7 Market Segmentation by Therapy

  • 7.1 Market segments
  • Exhibit 47: Chart on Therapy - Market share 2022-2027 (%)
  • Exhibit 48: Data Table on Therapy - Market share 2022-2027 (%)
  • 7.2 Comparison by Therapy
  • Exhibit 49: Chart on Comparison by Therapy
  • Exhibit 50: Data Table on Comparison by Therapy
  • 7.3 Pharmacological therapies - Market size and forecast 2022-2027
  • Exhibit 51: Chart on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 52: Data Table on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Chart on Pharmacological therapies - Year-over-year growth 2022-2027 (%)
  • Exhibit 54: Data Table on Pharmacological therapies - Year-over-year growth 2022-2027 (%)
  • 7.4 Non pharmacological therapies - Market size and forecast 2022-2027
  • Exhibit 55: Chart on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 56: Data Table on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Chart on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)
  • Exhibit 58: Data Table on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)
  • 7.5 Market opportunity by Therapy
  • Exhibit 59: Market opportunity by Therapy ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 63: Chart on Geographic comparison
  • Exhibit 64: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Germany - Market size and forecast 2022-2027
  • Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.9 China - Market size and forecast 2022-2027
  • Exhibit 89: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 90: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.10 UK - Market size and forecast 2022-2027
  • Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.11 Japan - Market size and forecast 2022-2027
  • Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 101: Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 102: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 104: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 105: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 106: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 107: Matrix on vendor position and classification
  • 12.3 Apotex Inc.
  • Exhibit 108: Apotex Inc. - Overview
  • Exhibit 109: Apotex Inc. - Product / Service
  • Exhibit 110: Apotex Inc. - Key offerings
  • 12.4 Assertio Therapeutics Inc.
  • Exhibit 111: Assertio Therapeutics Inc. - Overview
  • Exhibit 112: Assertio Therapeutics Inc. - Product / Service
  • Exhibit 113: Assertio Therapeutics Inc. - Key offerings
  • 12.5 AstraZeneca Plc
  • Exhibit 114: AstraZeneca Plc - Overview
  • Exhibit 115: AstraZeneca Plc - Product / Service
  • Exhibit 116: AstraZeneca Plc - Key news
  • Exhibit 117: AstraZeneca Plc - Key offerings
  • 12.6 Cadila Pharmaceuticals Ltd.
  • Exhibit 118: Cadila Pharmaceuticals Ltd. - Overview
  • Exhibit 119: Cadila Pharmaceuticals Ltd. - Product / Service
  • Exhibit 120: Cadila Pharmaceuticals Ltd. - Key offerings
  • 12.7 Cipla Ltd.
  • Exhibit 121: Cipla Ltd. - Overview
  • Exhibit 122: Cipla Ltd. - Business segments
  • Exhibit 123: Cipla Ltd. - Key news
  • Exhibit 124: Cipla Ltd. - Key offerings
  • Exhibit 125: Cipla Ltd. - Segment focus
  • 12.8 Daiichi Sankyo Co. Ltd.
  • Exhibit 126: Daiichi Sankyo Co. Ltd. - Overview
  • Exhibit 127: Daiichi Sankyo Co. Ltd. - Business segments
  • Exhibit 128: Daiichi Sankyo Co. Ltd. - Key news
  • Exhibit 129: Daiichi Sankyo Co. Ltd. - Key offerings
  • Exhibit 130: Daiichi Sankyo Co. Ltd. - Segment focus
  • 12.9 Dr Reddys Laboratories Ltd.
  • Exhibit 131: Dr Reddys Laboratories Ltd. - Overview
  • Exhibit 132: Dr Reddys Laboratories Ltd. - Business segments
  • Exhibit 133: Dr Reddys Laboratories Ltd. - Key offerings
  • Exhibit 134: Dr Reddys Laboratories Ltd. - Segment focus
  • 12.10 Eli Lilly and Co.
  • Exhibit 135: Eli Lilly and Co. - Overview
  • Exhibit 136: Eli Lilly and Co. - Product / Service
  • Exhibit 137: Eli Lilly and Co. - Key offerings
  • 12.11 Endo International Plc
  • Exhibit 138: Endo International Plc - Overview
  • Exhibit 139: Endo International Plc - Business segments
  • Exhibit 140: Endo International Plc - Key news
  • Exhibit 141: Endo International Plc - Key offerings
  • Exhibit 142: Endo International Plc - Segment focus
  • 12.12 Hikma Pharmaceuticals Plc
  • Exhibit 143: Hikma Pharmaceuticals Plc - Overview
  • Exhibit 144: Hikma Pharmaceuticals Plc - Business segments
  • Exhibit 145: Hikma Pharmaceuticals Plc - Key offerings
  • Exhibit 146: Hikma Pharmaceuticals Plc - Segment focus
  • 12.13 Johnson and Johnson
  • Exhibit 147: Johnson and Johnson - Overview
  • Exhibit 148: Johnson and Johnson - Business segments
  • Exhibit 149: Johnson and Johnson - Key news
  • Exhibit 150: Johnson and Johnson - Key offerings
  • Exhibit 151: Johnson and Johnson - Segment focus
  • 12.14 Lupin Ltd.
  • Exhibit 152: Lupin Ltd. - Overview
  • Exhibit 153: Lupin Ltd. - Product / Service
  • Exhibit 154: Lupin Ltd. - Key news
  • Exhibit 155: Lupin Ltd. - Key offerings
  • 12.15 Novartis AG
  • Exhibit 156: Novartis AG - Overview
  • Exhibit 157: Novartis AG - Business segments
  • Exhibit 158: Novartis AG - Key offerings
  • Exhibit 159: Novartis AG - Segment focus
  • 12.16 Pfizer Inc.
  • Exhibit 160: Pfizer Inc. - Overview
  • Exhibit 161: Pfizer Inc. - Product / Service
  • Exhibit 162: Pfizer Inc. - Key news
  • Exhibit 163: Pfizer Inc. - Key offerings
  • 12.17 Viatris Inc.
  • Exhibit 164: Viatris Inc. - Overview
  • Exhibit 165: Viatris Inc. - Business segments
  • Exhibit 166: Viatris Inc. - Key offerings
  • Exhibit 167: Viatris Inc. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 168: Inclusions checklist
  • Exhibit 169: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 170: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 171: Research methodology
  • Exhibit 172: Validation techniques employed for market sizing
  • Exhibit 173: Information sources
  • 13.5 List of abbreviations
  • Exhibit 174: List of abbreviations